FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marita Kailajärvi

Research Profile

Disorders

Procedures

Chemicals & Drugs

Anatomy

Brain

Co-author Network

Publications

TOP 3
Mikko Kuoppamäki; Kirsi Korpela; Reijo Marttila; Valtteri Kaasinen; Päivi Hartikainen; Jukka Lyytinen; Seppo Kaakkola; Jutta Hänninen; Eliisa Löyttyniemi; Marita E H Kailajärvi; Päivi Ruokoniemi; Juha Ellmén
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
J Hirvonen; Marita E H Kailajärvi; T Haltia; S Koskimies; Kjell Någren; P Virsu; Vesa Oikonen; Hannu Sipilä; P Ruokoniemi; K Virtanen; Mika Scheinin; Juha O Rinne
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
Nina Kemppainen; Sargo Aalto; Ian wilson; Kjell Någren; Semi Helin; Anna Brück; Vesa Oikonen; Marita E H Kailajärvi; Mika Scheinin; Matti Viitanen; Riitta Parkkola; Juha O Rinne
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marita Kailajärvi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Mikko Kuoppamäki; Kirsi Korpela; Reijo Marttila; Valtteri Kaasinen; Päivi Hartikainen; Jukka Lyytinen; Seppo Kaakkola; Jutta Hänninen; Eliisa Löyttyniemi; Marita E H Kailajärvi; Päivi Ruokoniemi; Juha Ellmén
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
European journal of clinical pharmacology 2009;65(5):443-55.
2009: J Hirvonen; Marita E H Kailajärvi; T Haltia; S Koskimies; Kjell Någren; P Virsu; Vesa Oikonen; Hannu Sipilä; P Ruokoniemi; K Virtanen; Mika Scheinin; Juha O Rinne
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
Clinical pharmacology and therapeutics 2009;85(5):506-12.
2007: Nina Kemppainen; Sargo Aalto; Ian wilson; Kjell Någren; Semi Helin; Anna Brück; Vesa Oikonen; Marita E H Kailajärvi; Mika Scheinin; Matti Viitanen; Riitta Parkkola; Juha O Rinne
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.
Neurology 2007;68(19):1603-6.
2006: Nina Kemppainen; Sargo Aalto; Ian wilson; Kjell Någren; Semi Helin; Anna Brück; Vesa Oikonen; Marita E H Kailajärvi; Mika Scheinin; Matti Viitanen; Riitta Parkkola; Juha O Rinne
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.
Neurology 2006;67(9):1575-80.
2004: Marita E H Kailajärvi; Eeva K Salminen; Outi M M Paija; Arja M Virtanent; Aila Leino; Kerttu A Irjala
Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy.
Anticancer research 2004;24(2C):1271-4.
2001: Marita E H Kailajärvi; Outi Ahokoski; Arja Virtanen; Eeva Salminen; Kerttu Irjala
Early effects of 5-fluorouracil, epirubicin and cyclophosphamide therapy on common laboratory tests.
Anticancer research 2001;21(4B):2867-72.
2000: K Laine; JJ Forsström; PE Grönroos; K Irjala; Marita E H Kailajärvi; Mika Scheinin
Frequency and clinical outcome of potentially harmful drug metabolic interactions in patients hospitalized on internal and pulmonary medicine wards: focus on warfarin and cisapride.
Therapeutic drug monitoring 2000;22(5):503-9.
2000: Marita E H Kailajärvi; T Takala; PE Grönroos; N Tryding; J Viikari; Kerttu Irjala; JJ Forsström
Reminders of drug effects on laboratory test results.
Clinical chemistry 2000;46(9):1395-400.
2000: Marita E H Kailajärvi; Outi Ahokoski; Arja Virtanen; Eeva Salminen; Kerttu Irjala
Alterations in laboratory test results during adjuvant breast cancer treatment.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(5):443-51.
2000: Marita E H Kailajärvi; Outi Ahokoski; Arja Virtanen; Eeva Salminen; Kerttu Irjala
Early effects of adjuvant tamoxifen therapy on serum hormones, proteins and lipids.
Anticancer research 2000;20(2B):1323-7.
1998: T I Takala; JJ Forsström; PE Grönroos; Marita E H Kailajärvi; Kerttu Irjala
[Support to clinician's decision making--automatic comments about drug effects on laboratory results].
Duodecim; lääketieteellinen aikakauskirja 1998;114(14):1387-92.